{"id":80251,"date":"2024-12-27T15:39:00","date_gmt":"2024-12-27T15:39:00","guid":{"rendered":"https:\/\/www.cofb.org\/?p=80251"},"modified":"2025-01-07T15:41:28","modified_gmt":"2025-01-07T15:41:28","slug":"farmaceutics-i-farmaceutiques-de-diversos-ambits-sactualitzen-en-el-maneig-de-les-hiperlipemies-i-el-pacient-amb-risc-cardiovascular","status":"publish","type":"post","link":"https:\/\/www.cofb.org\/ca\/2024\/12\/27\/farmaceutics-i-farmaceutiques-de-diversos-ambits-sactualitzen-en-el-maneig-de-les-hiperlipemies-i-el-pacient-amb-risc-cardiovascular\/","title":{"rendered":"Farmac\u00e8utics i farmac\u00e8utiques de diversos \u00e0mbits s\u2019actualitzen en el maneig de les hiperlip\u00e8mies i el pacient amb risc cardiovascular"},"content":{"rendered":"\n

El passat 10 de desembre, el Col\u00b7legi de Farmac\u00e8utics de Barcelona (COFB)<\/strong>, amb la col\u00b7laboraci\u00f3 de la Societat Catalana de Farm\u00e0cia Cl\u00ednica (SCFC)<\/a>, va organitzar la formaci\u00f3 \u201cActualitzaci\u00f3 en el maneig de les hiperlip\u00e8mies i el pacient amb risc cardiovascular\u201d<\/strong>, amb el patrocini d\u2019AMGEN<\/a>. La formaci\u00f3, adre\u00e7ada a farmac\u00e8utics\/ques d\u2019hospital, d\u2019atenci\u00f3 prim\u00e0ria i comunit\u00e0ria<\/strong>, va anar a c\u00e0rrec de Llu\u00eds Recasens<\/strong>, cardi\u00f2leg i cap cl\u00ednic del Servei de Cardiologia de l\u2019Hospital del Mar; Manuela Gonz\u00e1lez<\/strong>, farmac\u00e8utica adjunta del Servei de Farm\u00e0cia Hospital\u00e0ria de l\u2019Hospital Universitari Parc Taul\u00ed; Meritxell Royuela<\/strong>, metgessa internista i responsable de la Unitat de L\u00edpids i Risc Vascular d’Althaia, Xarxa Assistencial Universit\u00e0ria de Manresa; Mar\u00eda Eugenia Navarrete<\/strong>, farmac\u00e8utica adjunta del Servei de Farm\u00e0cia del Parc de Salut Mar; Eloi Merencio<\/strong>, farmac\u00e8utic comunitari a la farm\u00e0cia Naudin de Barcelona i professor associat del Grau de Farm\u00e0cia de la Universitat Ramon Llull; i Sara Gallardo<\/strong>, farmac\u00e8utica a l\u2019\u00c0rea de Suport al Medicament i Servei de Farm\u00e0cia, a la ger\u00e8ncia d\u2019Atenci\u00f3 Prim\u00e0ria i a la Comunitat Barcelona Litoral-Esquerra, ger\u00e8ncia d\u2019Atenci\u00f3 Prim\u00e0ria i a la Comunitat Barcelona Muntanya-Dreta \u00c0mbit Territorial Barcelona de l\u2019Institut Catal\u00e0 de la Salut (ICS). Els vocals del COFB d\u2019Hospitals, David Conde<\/strong>, d\u2019Atenci\u00f3 Prim\u00e0ria, Cristina Morales<\/strong>, i d\u2019Oficina de Farm\u00e0cia, Merc\u00e8 Barau<\/strong>, van coordinar la sessi\u00f3.<\/p>\n\n\n\n

\"Merc\u00e8<\/a>
Merc\u00e8 Barau (esquerra) i Cristina Morales (dreta) presentant la formaci\u00f3 sobre el maneig de les hiperlip\u00e8mies i el pacient amb risc cardiovascular. <\/figcaption><\/figure>\n\n\n\n

Els objectius <\/strong>de la formaci\u00f3 van ser con\u00e8ixer l\u2019avaluaci\u00f3 i maneig del pacient amb risc cardiovascular<\/strong>, revisar l\u2019arsenal terap\u00e8utic disponible pel tractament de les dislip\u00e8mies<\/strong>, compartir els processos assistencials<\/strong> i la implicaci\u00f3 del farmac\u00e8utic<\/strong>.<\/p>\n\n\n\n

Per comen\u00e7ar, la vocal d\u2019Atenci\u00f3 Prim\u00e0ria del COFB, Cristina Morales<\/strong>, va explicar que la formaci\u00f3 integra els diferents perfils assistencials<\/strong> que \u201cacompanyem al pacient afectat d\u2019una malaltia cardiovascular\u201d<\/strong>. En aquest sentit, la vocal de farm\u00e0cia comunit\u00e0ria, Merc\u00e8 Barau<\/strong>, va afegir que les tres vocalies aborden la farmacologia en pacients amb malalties cardiovasculars des d\u2019un aspecte diferent. \u201cEl risc cardiovascular \u00e9s la primera causa de mort en els pa\u00efsos occidentals, sobretot en dones\u201d<\/strong>, va assegurar Barau. Al llarg de la formaci\u00f3, es va donar resposta a diferents q\u00fcestions que va plantejar la vocal de Farm\u00e0cia Comunit\u00e0ria: Estem manejant adequadament els f\u00e0rmacs pel colesterol, com els fibrats o les estatines?<\/strong> Potser la dosificaci\u00f3 de les estatines no hauria de ser igual en una dona de 50 kg que en un home de 80 kg?<\/strong><\/p>\n\n\n\n

Classificaci\u00f3 del risc cardiovascular<\/strong><\/h2>\n\n\n\n

Sobre el risc cardiovascular en va parlar Llu\u00eds Recasens<\/strong>, cardi\u00f2leg i cap cl\u00ednic del Servei de Cardiologia de l\u2019Hospital del Mar. Per fer-ho, va repassar la hist\u00f2ria dels \u201cscores\u201d<\/strong> que s\u2019han fet servir per calcular el risc cardiovascular i les seves difer\u00e8ncies<\/strong> pel que fa als punts de tall i altres factors. L\u2019any 1948, a EUA, va ser la primera vegada que es va calcular el risc cardiovascular, a trav\u00e9s de l\u2019estudi de Framingham, va explicar Recasens. En total es van fer tres cohorts, els anys 1948, 1971 i 2002, en els quals es van anar afegint par\u00e0metres per valorar el risc. \u00a0<\/p>\n\n\n\n

\"Llu\u00eds<\/a>
Llu\u00eds Recasens en un moment de la seva exposici\u00f3 sobre la classificaci\u00f3 del risc cardiovascular.<\/figcaption><\/figure>\n\n\n\n

Recasens va compartir les guies de l\u2019European Society of Cardiology (ESC) de 2019 i 2021<\/strong> i va especificar els principals canvis en criteris d\u2019aquestes. Alhora, que va mostrar per qu\u00e8 \u00e9s important com es calcula el risc cardiovascular, els modificadors de risc a tenir presents i els tractaments possibles per baixar el colesterol.<\/strong><\/p>\n\n\n\n

Arsenal terap\u00e8utic<\/strong><\/h2>\n\n\n\n

Pel que fa als f\u00e0rmacs a utilitzar en va profunditzar Manuela Gonz\u00e1lez<\/strong>, farmac\u00e8utica adjunta del Servei de Farm\u00e0cia Hospital\u00e0ria de l\u2019Hospital Universitari Parc Taul\u00ed. Gonz\u00e1lez va resumir tot l\u2019arsenal terap\u00e8utic disponible<\/strong>, tot detallant els efectes secundaris i possibilitats de combinaci\u00f3. La farmac\u00e8utica va indicar que una malaltia cardiovascular est\u00e0 relacionada, principalment, amb el colesterol LDL i altres com l\u2019apolipoprote\u00efna B o les VLDL.<\/p>\n\n\n\n

\"Manuela<\/a>
Manuela Gonz\u00e1lez durant la seva intervenci\u00f3. <\/figcaption><\/figure>\n\n\n\n

Aix\u00ed doncs, va fer refer\u00e8ncia a les diferents opcions farmacol\u00f2giques hipolipemiants<\/strong>, segons el perfil del pacient, com s\u00f3n: els inhibidors de la s\u00edntesi de colesterol, estatines; els inhibidors de l\u2019absorci\u00f3 d\u2019\u00e0cids biliars; els inhibidors de l\u2019absorci\u00f3 del colesterol; els fibrats; els \u00e8sters et\u00edlics d’\u00e0cids grassos; l\u2019\u00e0cid nicot\u00ednic; l\u2019\u00e0cid bempedo\u00efc; els Inhibidors de la PCSK9; i els inhibidors s\u00edntesi de la PCSK9. Gonz\u00e1lez va concloure assegurant que \u201cles guies de pr\u00e0ctica cl\u00ednica es van actualitzant segons tenim noves alternatives terap\u00e8utiques\u201d<\/strong>, tot remarcant que \u201cla dieta i el canvi a h\u00e0bits saludables s\u00f3n essencials per valorar l\u2019efectivitat dels tractaments\u201d<\/strong>.<\/p>\n\n\n\n

Noves guies i recomanacions pel maneig de la dislip\u00e8mia<\/strong><\/h2>\n\n\n\n

A continuaci\u00f3, Meritxell Royuela<\/strong>, metgessa internista i responsable de la Unitat de L\u00edpids i Risc Vascular d’Althaia, Xarxa Assistencial Universit\u00e0ria de Manresa, va repassar les noves guies i recomanacions pel maneig de la dislip\u00e8mia. <\/strong>Va fer menci\u00f3 de la \u201cGuia de l\u00edpids i risc cardiovascular\u201d<\/strong> del CatSalut, la \u201cGuidelines for the management of dyslipidaemias: l\u00edpid modification to reduce cardiovascular risck<\/em>\u201d <\/strong>de la European Society of Cardiology (ESC) de l\u2019any 2019 i 2021, i la \u201cGuia cl\u00ednica sobre el maneig de les dislip\u00e8mies per la prevenci\u00f3 cardiovascular\u201d<\/strong> de la Xarxa d\u2019Unitats de L\u00edpids i Arteriosclerosi de Catalunya. Tanmateix, va fer refer\u00e8ncia al \u201cConsens catal\u00e0 sobre el control i maneig de la dislip\u00e8mia en prevenci\u00f3 secund\u00e0ria vascular<\/strong>\u201d o a les recomanacions cl\u00edniques de la Sociedad Espa\u00f1ola de Arteriosclerosis (SEA).<\/p>\n\n\n\n

\"\"<\/a><\/figure>\n\n\n\n

Per altra banda, a partir de les \u201cRecomanacions nutricionals saludables i d\u2019exercici f\u00edsic\u201d<\/strong> de la Xarxa d\u2019Unitats de L\u00edpids i Arteriosclerosi de Catalunya, la doctora va profunditzar en com pautar una dieta saludable<\/strong>, tot recalcant la import\u00e0ncia de l\u2019exercici f\u00edsic<\/strong>.<\/p>\n\n\n\n

Abordatge de pacients amb molt alt risc cardiovascular<\/strong><\/h2>\n\n\n\n

Seguidament, Llu\u00eds Recasens<\/strong>, cardi\u00f2leg i cap cl\u00ednic del Servei de Cardiologia de l\u2019Hospital del Mar, i Meritxell Royuela<\/strong>, metgessa internista i responsable de la Unitat de L\u00edpids i Risc Vascular d’Althaia, Xarxa Assistencial Universit\u00e0ria de Manresa, van tornar a intervenir per parlar sobre l\u2019abordatge de pacients amb molt alt risc cardiovascular i sobre la import\u00e0ncia de la prevenci\u00f3 secund\u00e0ria<\/strong>. Aix\u00ed doncs, Recasens va posar el focus en l\u2019abordatge del pacient amb S\u00edndrome Coronari Agut. \u201cUn 18,3% l\u2019any, de tots els pacients que han ingressat per S\u00edndrome Coronari Agut, tindr\u00e0 un esdeveniment cardiovascular, per aix\u00f2 cal procurar disminuir aquest percentatge\u201d<\/strong>, va especificar el doctor. Alhora, va afegir que \u201cel colesterol junt amb fumar s\u00f3n els factors de risc que predisposen a patir m\u00e9s risc cardiovascular\u201d<\/strong>. Aix\u00ed doncs, el doctor va fer \u00e8mfasi en la prevenci\u00f3 secund\u00e0ria a trav\u00e9s de la qual \u201cbusquem estabilitzar la placa\u201d<\/strong>.<\/p>\n\n\n\n

La doctora Meritxell Royuela va abordar els altres grups de pacients amb molt alt risc cardiovascular <\/strong>amb malaltia cardiovascular establerta, diabetis mellitus tipus 1 i 2, malaltia renal cr\u00f2nica, hipercolesterol\u00e8mia familiar o un factor de risc extremadament elevat.<\/p>\n\n\n\n

\n\n\n\n

Paper del farmac\u00e8utic per al bon control, adher\u00e8ncia i seguiment del risc cardiovascular<\/strong><\/h2>\n\n\n\n

Per tancar la formaci\u00f3, Mar\u00eda Eugenia Navarrete<\/strong>, farmac\u00e8utica adjunta del Servei de Farm\u00e0cia del Parc de Salut Mar, Eloi Merencio<\/strong>, farmac\u00e8utic comunitari a la farm\u00e0cia Naudin de Barcelona i professor associat del Grau de Farm\u00e0cia de la Universitat Ramon Llull, i Sara Gallardo<\/strong>, farmac\u00e8utica d\u2019Atenci\u00f3 Prim\u00e0ria i especialista en Farm\u00e0cia Hospital\u00e0ria, van intervenir per exposar quin \u00e9s el paper del farmac\u00e8utic per al bon control, adher\u00e8ncia i seguiment del risc cardiovascular<\/strong>, aix\u00ed com de les claus de l\u2019\u00e8xit de l\u2019atenci\u00f3 farmac\u00e8utica i coordinaci\u00f3 assistencial<\/strong>.<\/p>\n\n\n\n

La farmac\u00e8utica adjunta del Servei de Farm\u00e0cia del Parc de Salut Mar, Mar\u00eda Eugenia Navarrete<\/strong>, va comentar que amb l\u2019arribada del pacient a l\u2019hospital, \u201cl\u2019especialista l\u2019avalua i, si es considera candidat als tractaments hospitalaris, es presenta al comit\u00e8 de l\u00edpids i es decideix si es tira endavant el tractament i el f\u00e0rmac\u201d<\/strong>. Tamb\u00e9 va exposar en qu\u00e8 consisteix la visita d\u2019inici en el servei de farm\u00e0cia i com realitzen el seguiment dels pacients.<\/p>\n\n\n\n

\n
\"Mar\u00eda<\/a>
Mar\u00eda Eugenia Navarrete impartint la seva presentaci\u00f3. <\/figcaption><\/figure>\n\n\n\n
\"Eloi<\/a>
Eloi Merencio en un moment de la seva intervenci\u00f3. <\/figcaption><\/figure>\n\n\n\n
\"Sara<\/a>
Sara Gallardo durant la seva exposici\u00f3. <\/figcaption><\/figure>\n<\/figure>\n\n\n\n

Per la seva banda, Eloi Merencio<\/strong>, farmac\u00e8utic comunitari a la farm\u00e0cia Naudin de Barcelona i professor associat del Grau de Farm\u00e0cia de la Universitat Ramon Llull, va apuntar quin \u00e9s el paper dels farmac\u00e8utics\/ques comunitaris en l\u2019abordatge de les hiperlip\u00e8mies<\/strong>. En aquest sentit, va fer refer\u00e8ncia al Diagrama del Servei de dispensaci\u00f3<\/strong> i va indicar que \u00e9s important preguntar per les 5 W (qu\u00e8, quan, on, qui i per qu\u00e8) o formular preguntes obertes per poder detectar els problemes relacionats amb la medicaci\u00f3, entre altres q\u00fcestions.<\/p>\n\n\n\n

Finalment, la farmac\u00e8utica d\u2019Atenci\u00f3 Prim\u00e0ria, Sara Gallardo<\/strong>, va oferir la seva visi\u00f3 com a farmac\u00e8utica d\u2019atenci\u00f3 prim\u00e0ria, que va remarcar que el \u201cpilar b\u00e0sic com a farmac\u00e8utics d\u2019atenci\u00f3 prim\u00e0ria \u00e9s la translaci\u00f3 del coneixement tant a professionals com a pacients\u201d<\/strong>. Gallardo va detallar les eines d\u2019ajuda a la prescripci\u00f3 que disposa un farmac\u00e8utic\/a d\u2019atenci\u00f3 prim\u00e0ria <\/strong>per ajustar els tractaments al m\u00e0xim possible, aix\u00ed com les estrat\u00e8gies de desprescripci\u00f3<\/strong> i la revisi\u00f3 de la medicaci\u00f3 centrada en la persona<\/strong>.<\/p>\n\n\n\n<\/div>\n\n\n\n

\n
<\/div>\n\n\n\n
<\/div>\n\n\n\n
<\/div>\n\n\n\n
\n

Amb la col\u00b7laboraci\u00f3 de:<\/strong><\/p>\n\n\n\n

\"\"<\/a><\/figure>\n<\/div>\n<\/div>\n\n\n\n
\n
<\/div>\n\n\n\n
<\/div>\n\n\n\n
<\/div>\n\n\n\n
\n

Amb el patrocini de:<\/strong><\/p>\n\n\n\n

\"\"<\/a><\/figure>\n<\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

El passat 10 de desembre, el Col\u00b7legi de Farmac\u00e8utics de Barcelona (COFB), amb la col\u00b7laboraci\u00f3 de la Societat Catalana de Farm\u00e0cia Cl\u00ednica (SCFC), va organitzar la formaci\u00f3 \u201cActualitzaci\u00f3 en el maneig de les hiperlip\u00e8mies i el pacient amb risc cardiovascular\u201d, amb el patrocini d\u2019AMGEN. La formaci\u00f3, adre\u00e7ada a farmac\u00e8utics\/ques d\u2019hospital, […]<\/p>\n","protected":false},"author":3,"featured_media":80271,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_uag_custom_page_level_css":"","site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"disabled","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"set","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"categories":[23,57],"tags":[5062,3712,18,19,5209,52,4726,53,171,70,5208,290,3479,63,78,5203,5205,5204,1013,484,5207],"class_list":["post-80251","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-destacats","category-mon-collegial","tag-arsenal-terapeutic","tag-cardiovascular","tag-cofb","tag-collegi-de-farmaceutics-de-barcelona","tag-dislipemia","tag-farmaceutic","tag-farmaceutica","tag-farmaceutics","tag-farmaceutiques","tag-formacio","tag-hiperlipemies","tag-pacient","tag-risc-cardiovascular","tag-tractament","tag-tractament-farmacologic","tag-vocal-atencio-primaria","tag-vocal-dhospitals","tag-vocal-de-farmacia-comunitaria","tag-vocalia-datencio-primaria","tag-vocalia-dhospitals","tag-vocalia-de-farmacia-comunitaria"],"yoast_head":"\nFarmac\u00e8utics i farmac\u00e8utiques de diversos \u00e0mbits s\u2019actualitzen en el maneig de les hiperlip\u00e8mies i el pacient amb risc cardiovascular - Col\u00b7legi de Farmac\u00e8utics de Barcelona<\/title>\n<meta name=\"description\" content=\"El passat desembre, el COFB va organitzar la formaci\u00f3 \u201cActualitzaci\u00f3 en el maneig de les hiperlip\u00e8mies i el pacient amb risc cardiovascular\u201d\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.cofb.org\/ca\/2024\/12\/27\/farmaceutics-i-farmaceutiques-de-diversos-ambits-sactualitzen-en-el-maneig-de-les-hiperlipemies-i-el-pacient-amb-risc-cardiovascular\/\" \/>\n<meta property=\"og:locale\" content=\"ca_ES\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Farmac\u00e8utics i farmac\u00e8utiques de diversos \u00e0mbits s\u2019actualitzen en el maneig de les hiperlip\u00e8mies i el pacient amb risc cardiovascular - Col\u00b7legi de Farmac\u00e8utics de Barcelona\" \/>\n<meta property=\"og:description\" content=\"El passat desembre, el COFB va organitzar la formaci\u00f3 \u201cActualitzaci\u00f3 en el maneig de les hiperlip\u00e8mies i el pacient amb risc cardiovascular\u201d\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.cofb.org\/ca\/2024\/12\/27\/farmaceutics-i-farmaceutiques-de-diversos-ambits-sactualitzen-en-el-maneig-de-les-hiperlipemies-i-el-pacient-amb-risc-cardiovascular\/\" \/>\n<meta property=\"og:site_name\" content=\"Col\u00b7legi de Farmac\u00e8utics de Barcelona\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/farmaceuticsbcn\/\" \/>\n<meta property=\"article:published_time\" content=\"2024-12-27T15:39:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-01-07T15:41:28+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.cofb.org\/wp-content\/uploads\/2024\/12\/COFB_HIPERLIPEMIES_5-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1440\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Berta Mart\u00ednez\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@farmaceuticsbcn\" \/>\n<meta name=\"twitter:site\" content=\"@farmaceuticsbcn\" \/>\n<meta name=\"twitter:label1\" content=\"Escrit per\" \/>\n\t<meta name=\"twitter:data1\" content=\"Berta Mart\u00ednez\" \/>\n\t<meta name=\"twitter:label2\" content=\"Temps estimat de lectura\" \/>\n\t<meta name=\"twitter:data2\" content=\"11 minuts\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/www.cofb.org\/2024\/12\/27\/farmaceutics-i-farmaceutiques-de-diversos-ambits-sactualitzen-en-el-maneig-de-les-hiperlipemies-i-el-pacient-amb-risc-cardiovascular\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.cofb.org\/2024\/12\/27\/farmaceutics-i-farmaceutiques-de-diversos-ambits-sactualitzen-en-el-maneig-de-les-hiperlipemies-i-el-pacient-amb-risc-cardiovascular\/\"},\"author\":{\"name\":\"Berta Mart\u00ednez\",\"@id\":\"https:\/\/www.cofb.org\/#\/schema\/person\/f32de3b41b812c85ff923cb4cc849063\"},\"headline\":\"Farmac\u00e8utics i farmac\u00e8utiques de diversos \u00e0mbits s\u2019actualitzen en el maneig de les hiperlip\u00e8mies i el pacient amb risc cardiovascular\",\"datePublished\":\"2024-12-27T15:39:00+00:00\",\"dateModified\":\"2025-01-07T15:41:28+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.cofb.org\/2024\/12\/27\/farmaceutics-i-farmaceutiques-de-diversos-ambits-sactualitzen-en-el-maneig-de-les-hiperlipemies-i-el-pacient-amb-risc-cardiovascular\/\"},\"wordCount\":1693,\"publisher\":{\"@id\":\"https:\/\/www.cofb.org\/#organization\"},\"image\":{\"@id\":\"https:\/\/www.cofb.org\/2024\/12\/27\/farmaceutics-i-farmaceutiques-de-diversos-ambits-sactualitzen-en-el-maneig-de-les-hiperlipemies-i-el-pacient-amb-risc-cardiovascular\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.cofb.org\/wp-content\/uploads\/2024\/12\/COFB_HIPERLIPEMIES_5-scaled.jpg\",\"keywords\":[\"arsenal terap\u00e8utic\",\"cardiovascular\",\"COFB\",\"Col\u00b7legi de Farmac\u00e8utics de Barcelona\",\"dislip\u00e8mia\",\"farmac\u00e8utic\",\"farmac\u00e8utica\",\"farmac\u00e8utics\",\"farmac\u00e8utiques\",\"Formaci\u00f3\",\"hiperlip\u00e8mies\",\"pacient\",\"risc cardiovascular\",\"tractament\",\"tractament farmacol\u00f2gic\",\"Vocal Atenci\u00f3 Prim\u00e0ria\",\"Vocal d'Hospitals\",\"Vocal de Farm\u00e0cia Comunit\u00e0ria\",\"Vocalia d'Atenci\u00f3 Prim\u00e0ria\",\"Vocalia d'Hospitals\",\"Vocalia de Farm\u00e0cia Comunit\u00e0ria\"],\"articleSection\":[\"Destacats\",\"M\u00f3n col\u00b7legial\"],\"inLanguage\":\"ca\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.cofb.org\/2024\/12\/27\/farmaceutics-i-farmaceutiques-de-diversos-ambits-sactualitzen-en-el-maneig-de-les-hiperlipemies-i-el-pacient-amb-risc-cardiovascular\/\",\"url\":\"https:\/\/www.cofb.org\/2024\/12\/27\/farmaceutics-i-farmaceutiques-de-diversos-ambits-sactualitzen-en-el-maneig-de-les-hiperlipemies-i-el-pacient-amb-risc-cardiovascular\/\",\"name\":\"Farmac\u00e8utics i farmac\u00e8utiques de diversos \u00e0mbits s\u2019actualitzen en el maneig de les hiperlip\u00e8mies i el pacient amb risc cardiovascular - Col\u00b7legi de Farmac\u00e8utics de Barcelona\",\"isPartOf\":{\"@id\":\"https:\/\/www.cofb.org\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.cofb.org\/2024\/12\/27\/farmaceutics-i-farmaceutiques-de-diversos-ambits-sactualitzen-en-el-maneig-de-les-hiperlipemies-i-el-pacient-amb-risc-cardiovascular\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.cofb.org\/2024\/12\/27\/farmaceutics-i-farmaceutiques-de-diversos-ambits-sactualitzen-en-el-maneig-de-les-hiperlipemies-i-el-pacient-amb-risc-cardiovascular\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.cofb.org\/wp-content\/uploads\/2024\/12\/COFB_HIPERLIPEMIES_5-scaled.jpg\",\"datePublished\":\"2024-12-27T15:39:00+00:00\",\"dateModified\":\"2025-01-07T15:41:28+00:00\",\"description\":\"El passat desembre, el COFB va organitzar la formaci\u00f3 \u201cActualitzaci\u00f3 en el maneig de les hiperlip\u00e8mies i el pacient amb risc cardiovascular\u201d\",\"breadcrumb\":{\"@id\":\"https:\/\/www.cofb.org\/2024\/12\/27\/farmaceutics-i-farmaceutiques-de-diversos-ambits-sactualitzen-en-el-maneig-de-les-hiperlipemies-i-el-pacient-amb-risc-cardiovascular\/#breadcrumb\"},\"inLanguage\":\"ca\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.cofb.org\/2024\/12\/27\/farmaceutics-i-farmaceutiques-de-diversos-ambits-sactualitzen-en-el-maneig-de-les-hiperlipemies-i-el-pacient-amb-risc-cardiovascular\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"ca\",\"@id\":\"https:\/\/www.cofb.org\/2024\/12\/27\/farmaceutics-i-farmaceutiques-de-diversos-ambits-sactualitzen-en-el-maneig-de-les-hiperlipemies-i-el-pacient-amb-risc-cardiovascular\/#primaryimage\",\"url\":\"https:\/\/www.cofb.org\/wp-content\/uploads\/2024\/12\/COFB_HIPERLIPEMIES_5-scaled.jpg\",\"contentUrl\":\"https:\/\/www.cofb.org\/wp-content\/uploads\/2024\/12\/COFB_HIPERLIPEMIES_5-scaled.jpg\",\"width\":2560,\"height\":1440},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.cofb.org\/2024\/12\/27\/farmaceutics-i-farmaceutiques-de-diversos-ambits-sactualitzen-en-el-maneig-de-les-hiperlipemies-i-el-pacient-amb-risc-cardiovascular\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Inici\",\"item\":\"https:\/\/novaorg.cofb.net\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Farmac\u00e8utics i farmac\u00e8utiques de diversos \u00e0mbits s\u2019actualitzen en el maneig de les hiperlip\u00e8mies i el pacient amb risc cardiovascular\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.cofb.org\/#website\",\"url\":\"https:\/\/www.cofb.org\/\",\"name\":\"Col\u00b7legi de Farmac\u00e8utics de Barcelona\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/www.cofb.org\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.cofb.org\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"ca\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.cofb.org\/#organization\",\"name\":\"Col\u00b7legi de Farmac\u00e8utics de Barcelona\",\"url\":\"https:\/\/www.cofb.org\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"ca\",\"@id\":\"https:\/\/www.cofb.org\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.cofb.org\/wp-content\/uploads\/2023\/11\/cropped-Logotip-COFB.png\",\"contentUrl\":\"https:\/\/www.cofb.org\/wp-content\/uploads\/2023\/11\/cropped-Logotip-COFB.png\",\"width\":500,\"height\":105,\"caption\":\"Col\u00b7legi de Farmac\u00e8utics de Barcelona\"},\"image\":{\"@id\":\"https:\/\/www.cofb.org\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/farmaceuticsbcn\/\",\"https:\/\/twitter.com\/farmaceuticsbcn\",\"https:\/\/www.instagram.com\/farmaceuticsbcn\/\",\"https:\/\/www.linkedin.com\/company\/farmaceuticsbcn\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.cofb.org\/#\/schema\/person\/f32de3b41b812c85ff923cb4cc849063\",\"name\":\"Berta Mart\u00ednez\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"ca\",\"@id\":\"https:\/\/www.cofb.org\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/d4c584dab5da1ee9e3c3df161c0aabec7075cc8211cd46ffc79bfe177aa78b01?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/d4c584dab5da1ee9e3c3df161c0aabec7075cc8211cd46ffc79bfe177aa78b01?s=96&d=mm&r=g\",\"caption\":\"Berta Mart\u00ednez\"},\"url\":\"https:\/\/www.cofb.org\/ca\/author\/bmartinez\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Farmac\u00e8utics i farmac\u00e8utiques de diversos \u00e0mbits s\u2019actualitzen en el maneig de les hiperlip\u00e8mies i el pacient amb risc cardiovascular - Col\u00b7legi de Farmac\u00e8utics de Barcelona","description":"El passat desembre, el COFB va organitzar la formaci\u00f3 \u201cActualitzaci\u00f3 en el maneig de les hiperlip\u00e8mies i el pacient amb risc cardiovascular\u201d","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.cofb.org\/ca\/2024\/12\/27\/farmaceutics-i-farmaceutiques-de-diversos-ambits-sactualitzen-en-el-maneig-de-les-hiperlipemies-i-el-pacient-amb-risc-cardiovascular\/","og_locale":"ca_ES","og_type":"article","og_title":"Farmac\u00e8utics i farmac\u00e8utiques de diversos \u00e0mbits s\u2019actualitzen en el maneig de les hiperlip\u00e8mies i el pacient amb risc cardiovascular - Col\u00b7legi de Farmac\u00e8utics de Barcelona","og_description":"El passat desembre, el COFB va organitzar la formaci\u00f3 \u201cActualitzaci\u00f3 en el maneig de les hiperlip\u00e8mies i el pacient amb risc cardiovascular\u201d","og_url":"https:\/\/www.cofb.org\/ca\/2024\/12\/27\/farmaceutics-i-farmaceutiques-de-diversos-ambits-sactualitzen-en-el-maneig-de-les-hiperlipemies-i-el-pacient-amb-risc-cardiovascular\/","og_site_name":"Col\u00b7legi de Farmac\u00e8utics de Barcelona","article_publisher":"https:\/\/www.facebook.com\/farmaceuticsbcn\/","article_published_time":"2024-12-27T15:39:00+00:00","article_modified_time":"2025-01-07T15:41:28+00:00","og_image":[{"width":2560,"height":1440,"url":"https:\/\/www.cofb.org\/wp-content\/uploads\/2024\/12\/COFB_HIPERLIPEMIES_5-scaled.jpg","type":"image\/jpeg"}],"author":"Berta Mart\u00ednez","twitter_card":"summary_large_image","twitter_creator":"@farmaceuticsbcn","twitter_site":"@farmaceuticsbcn","twitter_misc":{"Escrit per":"Berta Mart\u00ednez","Temps estimat de lectura":"11 minuts"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.cofb.org\/2024\/12\/27\/farmaceutics-i-farmaceutiques-de-diversos-ambits-sactualitzen-en-el-maneig-de-les-hiperlipemies-i-el-pacient-amb-risc-cardiovascular\/#article","isPartOf":{"@id":"https:\/\/www.cofb.org\/2024\/12\/27\/farmaceutics-i-farmaceutiques-de-diversos-ambits-sactualitzen-en-el-maneig-de-les-hiperlipemies-i-el-pacient-amb-risc-cardiovascular\/"},"author":{"name":"Berta Mart\u00ednez","@id":"https:\/\/www.cofb.org\/#\/schema\/person\/f32de3b41b812c85ff923cb4cc849063"},"headline":"Farmac\u00e8utics i farmac\u00e8utiques de diversos \u00e0mbits s\u2019actualitzen en el maneig de les hiperlip\u00e8mies i el pacient amb risc cardiovascular","datePublished":"2024-12-27T15:39:00+00:00","dateModified":"2025-01-07T15:41:28+00:00","mainEntityOfPage":{"@id":"https:\/\/www.cofb.org\/2024\/12\/27\/farmaceutics-i-farmaceutiques-de-diversos-ambits-sactualitzen-en-el-maneig-de-les-hiperlipemies-i-el-pacient-amb-risc-cardiovascular\/"},"wordCount":1693,"publisher":{"@id":"https:\/\/www.cofb.org\/#organization"},"image":{"@id":"https:\/\/www.cofb.org\/2024\/12\/27\/farmaceutics-i-farmaceutiques-de-diversos-ambits-sactualitzen-en-el-maneig-de-les-hiperlipemies-i-el-pacient-amb-risc-cardiovascular\/#primaryimage"},"thumbnailUrl":"https:\/\/www.cofb.org\/wp-content\/uploads\/2024\/12\/COFB_HIPERLIPEMIES_5-scaled.jpg","keywords":["arsenal terap\u00e8utic","cardiovascular","COFB","Col\u00b7legi de Farmac\u00e8utics de Barcelona","dislip\u00e8mia","farmac\u00e8utic","farmac\u00e8utica","farmac\u00e8utics","farmac\u00e8utiques","Formaci\u00f3","hiperlip\u00e8mies","pacient","risc cardiovascular","tractament","tractament farmacol\u00f2gic","Vocal Atenci\u00f3 Prim\u00e0ria","Vocal d'Hospitals","Vocal de Farm\u00e0cia Comunit\u00e0ria","Vocalia d'Atenci\u00f3 Prim\u00e0ria","Vocalia d'Hospitals","Vocalia de Farm\u00e0cia Comunit\u00e0ria"],"articleSection":["Destacats","M\u00f3n col\u00b7legial"],"inLanguage":"ca"},{"@type":"WebPage","@id":"https:\/\/www.cofb.org\/2024\/12\/27\/farmaceutics-i-farmaceutiques-de-diversos-ambits-sactualitzen-en-el-maneig-de-les-hiperlipemies-i-el-pacient-amb-risc-cardiovascular\/","url":"https:\/\/www.cofb.org\/2024\/12\/27\/farmaceutics-i-farmaceutiques-de-diversos-ambits-sactualitzen-en-el-maneig-de-les-hiperlipemies-i-el-pacient-amb-risc-cardiovascular\/","name":"Farmac\u00e8utics i farmac\u00e8utiques de diversos \u00e0mbits s\u2019actualitzen en el maneig de les hiperlip\u00e8mies i el pacient amb risc cardiovascular - Col\u00b7legi de Farmac\u00e8utics de Barcelona","isPartOf":{"@id":"https:\/\/www.cofb.org\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.cofb.org\/2024\/12\/27\/farmaceutics-i-farmaceutiques-de-diversos-ambits-sactualitzen-en-el-maneig-de-les-hiperlipemies-i-el-pacient-amb-risc-cardiovascular\/#primaryimage"},"image":{"@id":"https:\/\/www.cofb.org\/2024\/12\/27\/farmaceutics-i-farmaceutiques-de-diversos-ambits-sactualitzen-en-el-maneig-de-les-hiperlipemies-i-el-pacient-amb-risc-cardiovascular\/#primaryimage"},"thumbnailUrl":"https:\/\/www.cofb.org\/wp-content\/uploads\/2024\/12\/COFB_HIPERLIPEMIES_5-scaled.jpg","datePublished":"2024-12-27T15:39:00+00:00","dateModified":"2025-01-07T15:41:28+00:00","description":"El passat desembre, el COFB va organitzar la formaci\u00f3 \u201cActualitzaci\u00f3 en el maneig de les hiperlip\u00e8mies i el pacient amb risc cardiovascular\u201d","breadcrumb":{"@id":"https:\/\/www.cofb.org\/2024\/12\/27\/farmaceutics-i-farmaceutiques-de-diversos-ambits-sactualitzen-en-el-maneig-de-les-hiperlipemies-i-el-pacient-amb-risc-cardiovascular\/#breadcrumb"},"inLanguage":"ca","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.cofb.org\/2024\/12\/27\/farmaceutics-i-farmaceutiques-de-diversos-ambits-sactualitzen-en-el-maneig-de-les-hiperlipemies-i-el-pacient-amb-risc-cardiovascular\/"]}]},{"@type":"ImageObject","inLanguage":"ca","@id":"https:\/\/www.cofb.org\/2024\/12\/27\/farmaceutics-i-farmaceutiques-de-diversos-ambits-sactualitzen-en-el-maneig-de-les-hiperlipemies-i-el-pacient-amb-risc-cardiovascular\/#primaryimage","url":"https:\/\/www.cofb.org\/wp-content\/uploads\/2024\/12\/COFB_HIPERLIPEMIES_5-scaled.jpg","contentUrl":"https:\/\/www.cofb.org\/wp-content\/uploads\/2024\/12\/COFB_HIPERLIPEMIES_5-scaled.jpg","width":2560,"height":1440},{"@type":"BreadcrumbList","@id":"https:\/\/www.cofb.org\/2024\/12\/27\/farmaceutics-i-farmaceutiques-de-diversos-ambits-sactualitzen-en-el-maneig-de-les-hiperlipemies-i-el-pacient-amb-risc-cardiovascular\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Inici","item":"https:\/\/novaorg.cofb.net\/"},{"@type":"ListItem","position":2,"name":"Farmac\u00e8utics i farmac\u00e8utiques de diversos \u00e0mbits s\u2019actualitzen en el maneig de les hiperlip\u00e8mies i el pacient amb risc cardiovascular"}]},{"@type":"WebSite","@id":"https:\/\/www.cofb.org\/#website","url":"https:\/\/www.cofb.org\/","name":"Col\u00b7legi de Farmac\u00e8utics de Barcelona","description":"","publisher":{"@id":"https:\/\/www.cofb.org\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.cofb.org\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"ca"},{"@type":"Organization","@id":"https:\/\/www.cofb.org\/#organization","name":"Col\u00b7legi de Farmac\u00e8utics de Barcelona","url":"https:\/\/www.cofb.org\/","logo":{"@type":"ImageObject","inLanguage":"ca","@id":"https:\/\/www.cofb.org\/#\/schema\/logo\/image\/","url":"https:\/\/www.cofb.org\/wp-content\/uploads\/2023\/11\/cropped-Logotip-COFB.png","contentUrl":"https:\/\/www.cofb.org\/wp-content\/uploads\/2023\/11\/cropped-Logotip-COFB.png","width":500,"height":105,"caption":"Col\u00b7legi de Farmac\u00e8utics de Barcelona"},"image":{"@id":"https:\/\/www.cofb.org\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/farmaceuticsbcn\/","https:\/\/twitter.com\/farmaceuticsbcn","https:\/\/www.instagram.com\/farmaceuticsbcn\/","https:\/\/www.linkedin.com\/company\/farmaceuticsbcn\/"]},{"@type":"Person","@id":"https:\/\/www.cofb.org\/#\/schema\/person\/f32de3b41b812c85ff923cb4cc849063","name":"Berta Mart\u00ednez","image":{"@type":"ImageObject","inLanguage":"ca","@id":"https:\/\/www.cofb.org\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/d4c584dab5da1ee9e3c3df161c0aabec7075cc8211cd46ffc79bfe177aa78b01?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/d4c584dab5da1ee9e3c3df161c0aabec7075cc8211cd46ffc79bfe177aa78b01?s=96&d=mm&r=g","caption":"Berta Mart\u00ednez"},"url":"https:\/\/www.cofb.org\/ca\/author\/bmartinez\/"}]}},"uagb_featured_image_src":{"full":["https:\/\/www.cofb.org\/wp-content\/uploads\/2024\/12\/COFB_HIPERLIPEMIES_5-scaled.jpg",2560,1440,false],"thumbnail":["https:\/\/www.cofb.org\/wp-content\/uploads\/2024\/12\/COFB_HIPERLIPEMIES_5-150x150.jpg",150,150,true],"medium":["https:\/\/www.cofb.org\/wp-content\/uploads\/2024\/12\/COFB_HIPERLIPEMIES_5-300x169.jpg",300,169,true],"medium_large":["https:\/\/www.cofb.org\/wp-content\/uploads\/2024\/12\/COFB_HIPERLIPEMIES_5-768x432.jpg",768,432,true],"large":["https:\/\/www.cofb.org\/wp-content\/uploads\/2024\/12\/COFB_HIPERLIPEMIES_5-1024x576.jpg",1024,576,true],"1536x1536":["https:\/\/www.cofb.org\/wp-content\/uploads\/2024\/12\/COFB_HIPERLIPEMIES_5-1536x864.jpg",1536,864,true],"2048x2048":["https:\/\/www.cofb.org\/wp-content\/uploads\/2024\/12\/COFB_HIPERLIPEMIES_5-2048x1152.jpg",2048,1152,true],"trp-custom-language-flag":["https:\/\/www.cofb.org\/wp-content\/uploads\/2024\/12\/COFB_HIPERLIPEMIES_5-18x10.jpg",18,10,true]},"uagb_author_info":{"display_name":"Berta Mart\u00ednez","author_link":"https:\/\/www.cofb.org\/ca\/author\/bmartinez\/"},"uagb_comment_info":0,"uagb_excerpt":"El passat 10 de desembre, el Col\u00b7legi de Farmac\u00e8utics de Barcelona (COFB), amb la col\u00b7laboraci\u00f3 de la Societat Catalana de Farm\u00e0cia Cl\u00ednica (SCFC), va organitzar la formaci\u00f3 \u201cActualitzaci\u00f3 en el maneig de les hiperlip\u00e8mies i el pacient amb risc cardiovascular\u201d, amb el patrocini d\u2019AMGEN. La formaci\u00f3, adre\u00e7ada a farmac\u00e8utics\/ques d\u2019hospital, […]","_links":{"self":[{"href":"https:\/\/www.cofb.org\/ca\/wp-json\/wp\/v2\/posts\/80251","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.cofb.org\/ca\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.cofb.org\/ca\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.cofb.org\/ca\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/www.cofb.org\/ca\/wp-json\/wp\/v2\/comments?post=80251"}],"version-history":[{"count":28,"href":"https:\/\/www.cofb.org\/ca\/wp-json\/wp\/v2\/posts\/80251\/revisions"}],"predecessor-version":[{"id":80331,"href":"https:\/\/www.cofb.org\/ca\/wp-json\/wp\/v2\/posts\/80251\/revisions\/80331"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.cofb.org\/ca\/wp-json\/wp\/v2\/media\/80271"}],"wp:attachment":[{"href":"https:\/\/www.cofb.org\/ca\/wp-json\/wp\/v2\/media?parent=80251"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.cofb.org\/ca\/wp-json\/wp\/v2\/categories?post=80251"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.cofb.org\/ca\/wp-json\/wp\/v2\/tags?post=80251"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}